Preview

Научно-практическая ревматология

Расширенный поиск

Иммунологические маркеры антифосфолипидного синдрома. Часть Iантифосфолипидные антитела

https://doi.org/10.14412/1995-4484-2009-586

Аннотация

По современным представлениям, важную роль в развитии аутоиммунной тромботической васкулопатии при антифосфолипидном синдроме (АФС) играют антитела к фосфолипидам (аФЛ), маркеры повреждения/дисфункции эндотелиальных клеток (ЭК) (растворимые клеточные молекулы адгезии – рКМА, антиген фактора Виллебранда– ФВАг), показатели активации клеточного иммунитета (цитокины, их растворимые рецепторы, растворимый CD40 лиганд, неоптерин), компоненты комплемента и белки острой фазы воспаления (С-реактивный белок – СРБ) [1-12].

Список литературы

1. <div><p>Насонов Е.Л. Антифосфолипидный синдром. М., Литтерра, 2004, 440 с.</p><p>De Groot P.G., Derksen R.H.W.M. Pathophysiology of the antiphospholipid syndrome. J. Thromb. Haemost., 2005, 5, 1854-60.</p><p>Pierangeli S.S., Espinola R.G., Liu X., Harris E.N. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ. Res., 2001, 88, 245-50.</p><p>Giannokopoulos B., Passam F., Rahgozar S., Krilis S.A. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood, 2007, 109, 422-30.</p><p>Rand J.H. Molecular pathogenesis of the antiphospholipid syndrome. Circ. Res., 2002, 90, 29-37.</p><p>Shoenfeld Y., Meroni P.L., Cervera R. Antiphospholipid syndrome dilemmas still be to solved: 2008 status. Ann. Rheum. Dis., 2008, 67, 438-42.</p><p>Александрова Е.Н., Новиков А.А., Решетняк Т.М. и соавт. Растворимые молекулы адгезии при антифосфолипидном синдроме, связанном с системной красной волчанкой, и первичном антифосфолипидном синдроме. Тер. архив, 2002, 23-7.</p><p>Александрова Е.Н., Новиков А.А., Решетняк Т.М. и соавт. Антитела к β2-гикопротеину 1 и антитела к кардиолипину при антифосфолипидном синдроме: анализ чувствительности и специфичности. Клин. мед., 2003, 9, 25-31.</p><p>Александрова Е.Н., Новиков А.А., Новикова Д.С. Лабораторная диагностика антифосфолипидного синдрома. Научно-практич. ревматол., 2004, 4, 47-52.</p><p>Александрова Е.Н., Новиков А.А., Попкова Т.В. и соавт. Растворимый лиганд CD40 при системной красной волчанке и антифосфолипидном синдроме. Тер. архив, 2006, 6, 35-9.</p><p>Александрова Е.Н., Новиков А.А., Решетняк Т.М. и соавт. Клинико-иммунологическая оценка высокочувствительного метода определения С-реактивного белка при антифосфолипидном синдроме. Научно-практич. ревматол., 2007, 1, 9-15.</p><p>Новиков А.А., Александрова Е.Н., Попкова Т.В. и соавт. Антиген фактора Виллебранда при системной красной волчанке и антифосфолипидном синдроме. Научно-практич. ревматол., 2004, 4, 35-8.</p><p>Reddel S.W., Krilis S.A. Testing for and clinical significance of anticardiolipin antibodies. Clin. Diagn. Lab. Immunol., 1999, 6, 775-82.</p><p>Roubey R.A. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum., 1996, 39, 1444-54.</p><p>Galli M., Comfurius H., Maasen C. et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet, 1990, 335, 1544-7.</p><p>Matsuura E., Igarashi M., Fujimoto K. et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet, 1990, 336, 177-8.</p><p>McNeil H.P., Simpson R.J., Chesterman C.N., Kliris S.A. Anti-phospholipid antibodies are directed against a complex antigen that induces a lipid-binding inhibitor of coagulation: beta2 glycoprotein I (apolipoprotein H). Proc. Natl. Acad. Sci. USA, 1990, 87, 4120-4.</p><p>Matsuura E., Dier K.J., Lopez L.R. β2-glycoprotein I antibodies. In: Y. Shoenfeld, M.E. Gershwin, P.L. Meroni. Autoantibodies 2nd ed. Oxford, Elsevier B.V., 2007, 687-93.</p><p>Hunt J., Krilis S. The fifth domain of beta2-glycoprotein I containes a phosphilipid binding site (cys281cys288), and region recognised by anticardiolipin antibodies. J.Immunol., 1994, 152, 653-9.</p><p>McNeeley P.A., Dlott J.S., Furie R.A. et al. Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. Thromb. Haemost., 2001, 86, 590-5.</p><p>Giles I.P., Isenberg D.A., Latchman D.S., Rahman A. How do antiphospholipid antibodies bind to β2-glycoprotein I. Arthritis Rheum., 2003, 48, 2111-21.</p><p>Pierangeli S.S., Harris E.N. In vivo models of thrombosis for the antiphospholipid syndrome. Lupus, 1996, 5, 451-5.</p><p>De Groot P.G., Horbach D.A., Derksen R.H. Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus, 1996, 5, 488-93.</p><p>Shibata S., Harpel P.C., Gharavi A. et al. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood, 1994, 83, 2532-40.</p><p>Schousboe I., Rasmussen M.S. Synchronized inhibition of the phospholipid mediated autoactivation of factor XII in plasma by beta 2-glycoprotein I and anti-beta 2-glycoprotein I. Thromb. Haemost., 1995, 73, 798-804.</p><p>Lutters B.C., Meijers J.C., Derksen R.H. et al. Dimers of beta 2-glycoprotein I mimic the in vitro effects of 35 beta 2-glycoprotein I-anti-beta 2-glycoprotein I antibody complexes. J. Biol. Chem., 2001, 276, 3060-7.</p><p>Wiener M.H., Burke M., Fried M., Yust I. Thromboagglutination by anticardiolipin antibody complex in the antiphospholipid syndrome: a possible mechanism of immune-mediated thrombosis. Thromb. Res., 2001, 103, 193-9.</p><p>Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am. J. Obstet. Gynecol., 1993,. 168, 206- 10.</p><p>Zhou H., Wolberg A.S., Roubey R.A. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood, 2004, 104, 2353-8.</p><p>Hamid C., Norgate K., D′Cruz D.P. Anti – β2GPI – antibody – induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome. Ann. Rheum. Dis., 2007, 66, 1000-7.</p><p>Rand J.H., Wu X.X. Antibody-mediated disruption of the annexin-V antithrombotic shield: a new mechanism for thrombosis in the antiphospholipid syndrome. Thromb. Haemost., 1999, 82, 649-55.</p><p>Kuwana M., Matsuura E., Kobayashi K. et al. Binding of beta 2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood, 2005, 105, 1552-7.</p><p>Buttari B., Profumo E., Mattei V. et al. Oxidized beta – glycoprotein I induces human dendritic cell maturation and promotes a T-helper type I response. Blood, 2005, 106, 3880-7.</p><p>Blank M., Krause I., Fridkin M., et al. Bacterial induction of autoantibodies to beta2-glycoprotein 1 account for the infectious etiology of antiphospholipid syndrome. J. Clin. Invest., 2002, 109, 798-804.</p><p>Iverson G.M., Victoria E.J., Marquis D.M. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc. Natl. Acad. Sci. U S A, 1998, 95, 15542-6.</p><p>Miyakis S., Lockshin M.D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost., 2006, 4, 295- 306.</p><p>Harris E.N. The Second International Anticardiolipin Standartization Workshop/The Kingston Antiphospholipid Study (KAPS) Group. Am. J. Clin. Pathol., 1990, 94, 476-84.</p><p>Loizou S., McCrea J.D., Rudge A.C. et al. Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin. Exp. Immunol., 1985, 62, 738-45.</p><p>Brandt J.T., Triplett D.A., Alving B., Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb. Haemost., 1995, 74,1185-90.</p><p>Roubey R.A., Maldonado M.A., Byrd S.N. Comparison of an enzyme-linked immunosorbent assay for antibodies to beta 2-glycoprotein I and a conventional anticardiolipin immunoassay. Arthritis Rheum., 1996, 39, 1606-7.</p><p>Reber G., Arvieux J., Comby E. et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The Working Group on Methodologies in Haemostasis from the GEHT (Groupe d’Etudes sur l’H mostase et la Thrombose). Thromb. Haemost., 1995, 73, 444-52.</p><p>Reber G., Schousboe I., Tincani A. et al. Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb. Haemost., 2002, 88, 66-73.</p><p>Andrian M.A., Colonna F., Morio F. et al. Comparison of different kits in the detection of autoantibodies to cardiolipin and beta2 glycoprotein 1. Rheumatol. (Oxford), 2004, 43, 181-5.</p><p>Tincani A., Allegri F., Sanmarco M. et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations – a cooperative project of the European Antiphospholipid Forum. Thromb. Haemost., 2001, 86, 575-83.</p><p>Petri M. Epidemiology of the antiphospholipid antibody syndrome. J. Autoimmun., 2000, 15, 145-51.</p><p>Cervera R., Piette J.C., Font J. et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum., 2002, 46, 1019.</p><p>Love P.E., Santoro S.A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann. Intern. Med., 1990, 112, 682-98.</p><p>McNeil H.P., Chesterman C.N., Krilis S.A. Immunology and clinical importance of antiphospholipid antibodies. Adv. Immunol., 1991, 49, 193-280.</p><p>Galli M., Luciani D., Bertolini G., Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood, 2003, 101, 1827-32.</p><p>Galli M., Luciani D., Bertolini G., Barbui T. Anti-β2 – glycoprotein I, antiprothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome. Blood, 2003, 102, 2717-23.</p><p>Bertolaccini M.L., Kamashta M.A. Laboratory diagnosis and management challenge in the antiphospholipid syndrome. Lupus, 2006, 15, 172-8.</p><p>Amengual O., Atsumi T., Khamashta M.A. et al. Specificity of ELISA for antibody to B2-glycoprotein I in patients with antiphospholipid syndrome. Br. J. Rheumatol., 1996, 35, 1239-43.</p><p>Cabiedes J., Cabral A., Alarcon-Segovia D. Clinical manifestation of the antiphospholipid syndrome in patients with systemic lupus erytematosus associate more strongly with anti-β2-glycoprotein-I than with antiphospholipid antibodies. J. Rheumatol., 1995, 22, 1899-906.</p><p>Campos L.M., Kiss M.H., D′Amico E.A., Silva C.A. Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus. Lupus, 2003, 12, 820-6.</p><p>Detkova D., Gil-Aquado A., Lavilla P. et al. Do antibodies to β2-glycoprotein I contribute to the better characterization of the antiphospholipid syndrome ? Lupus, 1999, 8, 430-8.</p><p>Guerin J., Feighery C., Sim R.B., Jackson J. Antibodies to β2-glycoprotein I – a specific marker for the antiphospholipid syndrome. Clin. Exp. Immunol., 1997, 109, 304-9.</p><p>Horbach D.A., Oort E.V., Donders R.C.J.M. Lupus anticoagulant is the strongest risk factor for both venous and artherial thrombosis in patients with systemic lupus erythematosus. Tromb. Haemost., 1996, 76, 916-24.</p><p>Musial J., Swadzba J., Motyl A. et al. Clinical significance of antiphospholipid protein antibodies. Receiver operating characteristics plot analysis. J. Rheumatol., 2003, 30, 723-30.</p><p>Wasmuth J.C., Minarro D.O., Homrighausen A. et al. Phoshpholipid autoantibodies and the antiphospholipid antibody syndrome: diagnostic accuracy of</p><p>methods studied by variation in ROC curves with number of clinical manifestations. Clin. Chem., 2002, 48, 1004-10.</p><p>Cucurull E., Espinoza L.R., Mendez E. et al. Anticardiolipin and anti-beta2 glycoprotein-I antibodies in patients with systemic lupus erythematosus: comparison between Colombians and Spaniards. Lupus, 1999, 8, 134-41.</p><p>Escalante A., Brey R.L., Mitchell B.D. et al. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am. J. Med., 1995, 98, 559-63.</p><p>Finazzi G., Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am. J. Med., 1996, 100, 530-6.</p><p>Tsutsumi A., Matsuura E., Ichikawa K. et al. Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum., 1996, 39, 1466-74.</p><p>Ginsburg K.S., Liang M.H., Newcomer L. et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann. Intern. Med., 1992, 117, 997-1002.</p><p>Schulman S., Svenungsson E., Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am. J. Med., 1998, 104, 332-8.</p><p>Wahl D.G., Guillemin F., de Maistre E. et al. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus – a meta-analysis. Lupus, 1997, 6, 467-73.</p><p>De Laat H.B., Derksen R.H., Urbanus R.T. et al. βeta2-glycoprotein I – dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood, 2004, 104, 3598-602.</p><p>De Laat H.B., Derksen R.H., Urbanus R.T., De Groot P.G. IgG antibodies that recognize epitope Gly40- Arg43 in domain I of βeta2-glycoprotein I cause LAC and their presence correlates strongly with thrombosis. Blood, 2005, 105, 1540-45.</p><p>Vinatier D., Dufour P., Cosson M., Houpeau J.L. Antiphospholipid syndrome and recurrent miscarriages. Eur. J. Obstet. Gynecol. Reprod. Biol., 2001, 96, 37-50.</p><p>Branch, DW, Khamashta, MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet. Gynecol., 2003, 101, 1333-40.</p><p>Gris J.C., Quere I., Sanmarco M. et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nimes Obstretricians and Haematologist Study – NOHA. Thromb. Haemost., 2000, 84, 228-36.</p><p>De Laat H.B., Derksen R.H.W.M., Mackie I.J. et al. Annexin A5 polymorphism (-1C→T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome. Ann. Rheum. Dis., 2006, 65, 1468-72. 37</p></div><br />


Рецензия

Для цитирования:


Alexandrova E.N., Новиков А.А., Решетняк Т.М., Насонов Е.Л. Иммунологические маркеры антифосфолипидного синдрома. Часть Iантифосфолипидные антитела. Научно-практическая ревматология. 2009;47(5):30-37. https://doi.org/10.14412/1995-4484-2009-586

For citation:


Alexandrova E.N., Novikov A.A., Reshetnyak T.M., Nasonov E.L. Immunological markers of antiphospholipid syndrome. Part I – antiphospholipid antibodies. Rheumatology Science and Practice. 2009;47(5):30-37. (In Russ.) https://doi.org/10.14412/1995-4484-2009-586

Просмотров: 789


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)